Seven in ten severe asthma patients meeting biologic criteria improved without a biologic

Design

Retrospective cohort from nationwide UK electronic records, trajectory clustering

Population

10,078 biologic-naive adults with severe asthma and ≥3 steroid-treated exacerbations in a year

Primary outcome

Exacerbation trajectory after first biologic-eligible year

Effect

Remitting-stable 70%; chronic-frequent 20%; refractory-frequent 10%

This study used nationwide UK primary care records to follow 10,078 biologic-naive adults with severe asthma from the first year in which they had three or more steroid-treated exacerbations — the point at which many would qualify for a biologic. Median age was 51 and 71% were women.

Three trajectories emerged. In 70%, exacerbations fell to fewer than three a year and stayed there, even as inhaled steroid doses were reduced. In 20%, exacerbations stayed frequent (median five a year), and in 10% patients needed more than ten oral steroid courses a year. The persistently frequent group had higher blood eosinophils (median 0.30 × 10⁹/L) than the others, a difference visible years before they became eligible. Remitters were least likely to have bronchiectasis but were otherwise similar.

Two things follow. First, a bad year is often followed by better ones, so some of the improvement attributed to biologics in practice is likely regression to the mean. Second, the patients who stay unwell look distinct early, and eosinophil history may help pick them out. This is observational and clustering-based, and it does not question the trial evidence that biologics work.

• Before starting a biologic after one bad year, check adherence, inhaler technique, triggers and comorbidities.
• Expect many patients with a year of frequent exacerbations to improve on optimised standard care.
• A history of raised blood eosinophils over several years marks patients likely to keep exacerbating.
• Screen for bronchiectasis in patients whose exacerbations persist.
• Judge a biologic's effect against the patient's trajectory, not only against the worst year.

Why it matters

Much of the improvement after a biologic is started may have happened anyway.

Don't overread it

This does not show biologics are ineffective; randomised trials establish their benefit.

The statistics, in plain English

The three groups come from a clustering method, which finds patterns in the data rather than testing a hypothesis. That 70% improved without a biologic is a descriptive finding, not a comparison with treatment.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.